Please login to the form below
Non-muscle-invasive bladder cancer
This page shows the latest Non-muscle-invasive bladder cancer news and features for those working in and with pharma, biotech and healthcare.
AZ withdraws Imfinzi in the US for advanced bladder cancer after post-marketing study fail
Despite the withdrawal, AZ still has several phase 3 trials testing Imfinzi in various treatment combinations for early- and late-stage bladder cancer. ... This includes the phase 3 NILE trial in metastatic disease, the phase 3 NIAGARA trial in muscle
Latest news
-
AstraZeneca’s Imfinzi fails first-line bladder cancer test
AZ’s head of oncology José Baselga said that Imfinzi is still in a “comprehensive” phase 3 programme in bladder cancer. ... pre-surgery) bladder cancer treatment, and the POTOMAC study, which include subjects with non-muscle invasive bladder
-
Tocagen merges with Forte Biosciences after brain cancer fail
of brain cancer. ... and non-muscle invasive bladder cancer.
-
Keytruda claims first place in bladder cancer race
for non-muscle-invasive bladder cancer (NMIBC), extending its lead in the checkpoint inhibitor market. ... NMIBC is the most commonly encountered form of bladder cancer, accounting for around 75% of the 80, 000 new cases of bladder cancer seen every year
-
FDA panel clears Keytruda for hard-to-treat bladder cancer
The Oncologic Drugs Advisory Committee (ODAC) voted nine to four that Keytruda (pembrolizumab) should be approved for the treatment of certain patients with high-risk, non-muscle-invasive bladder cancer (NMIBC), ... Merck estimates more than 80, 000 new
-
A look ahead to key trial readouts at ESMO
Merck &Co/MSD – already dominating non-small cell lung cancer with Keytruda (pembrolizumab) – will have overall survival data for its drug in first-line squamous head and neck cancer from the ... It will also have mid-stage data on the drug as a
More from news
Approximately 1 fully matching, plus 6 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2015
Immunomic Therapeutics will retain the rights to its LAMP-vax platform for other applications, including cancer immunotherapy. ... MCNA for non-muscle invasive bladder cancer (BLA filed). Licence. 137. Proteros biostructures/ Merck &Co.
-
Achieving consensus
Their joint aim: to facilitate uniform use of fluorescence cystoscopy in the diagnosis and follow up of bladder cancer, with the ultimate goal of improved care and better outcomes for patients. ... Despite widespread acceptance of the evidence for
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Sanofi Global Health unveils new nonprofit Impact brand
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- The Power of AI in Medical Education
- First evidence-based guide launched to put patients at heart of digital innovations
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- New Swiss research reveals how Omicron evades the immune system
- Evoke Kyne Named Communiqué Communications Consultancy of the Year 2021
- Michael Grela Elected President of the Society for Health Communication
- First evidence-based guide launched to put patients at heart of digital innovations
- Roche shares new positive Ocrevus data for MS patients
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- A creative awakening – how pharma is bringing innovation to the patient journey
- Country report: The healthcare market in South Korea
- European Commission approves potential new treatment for Pompe disease
PMHub
Dovetail
We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...
Latest intelligence
- Five big changes in the healthcare comms landscape
- The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- What communications are required for a successful launch...
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
